Location preference

Enter your country so we can show you products that are available for you.

Cell Therapy Technologies

Helping to put next-generation cell and gene therapies within reach

Cell and gene therapy developers and their healthcare partners are working to cure patients in a complex environment. Our role is to assist them from the earliest phases of process development to scaling up and out for clinical trials and commercialization.

With more than 40 years of proven expertise in cell collection and handling, and from cell expansion to fill and finish, we’re with you at the most critical points of your process. Our team is proud to deliver not only automated manufacturing platforms, but also data-based insights that can help you support better outcomes for patients.

Global Therapy Innovations at Terumo Blood and Cell Technologies

Did you know our cell and gene therapy and therapeutic apheresis teams work closely together as part of one unified Global Therapy Innovations business unit? The infrastructure helps us better serve customers, integrate disease expertise across the patient treatment journey, and support the expansion of therapeutic possibilities.

Integrate automation into your process

See how adopting modular automated solutions early in your cell production efforts can help you advance the development of novel therapies for the patients who need them. Maintain the integrity of your work as it progresses into later phases of development by streamlining and simplifying the most complex parts of your process — from cell collections to cell expansion to fill and finish.

Enable reproducible, scalable processes

Developers can use our Quantum Flex™ Cell Expansion System to expand multiple cell types, including mesenchymal stem cells (MSCs), T cells, fibroblasts, dendritic cells, and HEK 293T (for viral vector production).*

When comparing mesenchymal stromal cell production in flasks versus Quantum Flex, the automated platform showed an 88% reduction* in harvest time and labor hours.¹

Reduce variables in the work path and improve efficiency

Use of an automated bioreactor closed system has been shown to increase yields and reduce growing times for a variety of cell types.* In one report, City of Hope generated a GMP-grade lot of clinically viable neural stem cells within nine days with the Quantum™ Cell Expansion System, compared with six weeks using cell factories.²

Decrease open events with a closed cell culture environment

The closed environment of our bioreactor remains intact during the cell culture process, eliminating open events and hands-on tasks associated with manual flask-based culture.* One study from Baylor College of Medicine Center for Cell and Gene Therapy showed a 99.8% reduction in open events when using the Quantum system compared to an equivalent flask-based process.¹

Increase control over variability in your final steps

With the Finia™ Fill and Finish System, you can maintain cell viability of greater than 95% of the inlet cell viability throughout final formulation.* Plus, maintain uniformity of cell concentrations to within 5% on all final product bags and a QC bag.*

Leverage our insights

You are not in this alone. We believe that service, support, and training go hand-in-hand with innovation. Learn about Veda™ Solutions, our suite of solutions designed to help you elevate operations and meet your goals. Veda Solutions includes installation qualification (IQ)/operational qualification (OQ) services

If you’d like to learn more about our Cell Therapy Technologies solutions, please reach out today.

Disclaimers and notes

*Performance varies by user and is dependent on customer processes and materials.

  1. Hanley P, Mei Z, Durett A, et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy. 2014;16(8):1048-1058.
  2. Tirughana R, Metz MZ, Li Z, et al. GMP production and scale-up of adherent stem cells with a Quantum Cell Expansion System. Mol Ther Methods Clin Dev. 2018;10:48-56.
To top